Factors involved in the absence of sedative effects by second-generation antihistamines

Allergy: European Journal of Allergy and Clinical Immunology, Supplement

Volumn 55, Issue 60, 2000, Pages 5-10

  Timmerman, H ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZATADINE; CETIRIZINE; CHLORPHENIRAMINE; CYCLOHEXANE; DIMETINDENE; DIPHENHYDRAMINE; EPINASTINE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR; HYDROXYZINE; IMIPRAMINE; LORATADINE; MEPYRAMINE; OCTANOL; TEMELASTINE; TERFENADINE;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG TRANSPORT; HYDROPHOBICITY; IONIZATION; LIPOPHILICITY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SEDATION;

BLOOD-BRAIN BARRIER; BRAIN; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; HYPNOTICS AND SEDATIVES; P-GLYCOPROTEIN; RECEPTORS, HISTAMINE H1;

EID: 0034026908     PISSN: 01081675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. SCHWARTZ JC, ARRANG JM, GARBARG M, POLLARD H. Histaminergic transmission in mammalian brain. Physiol Rev 1991;71:1-51.
2. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, atopic eczema: ISAAC. Lancet 1998;351:1225-1232.
3. 2 antagonists. Neuropharmacology 1985;24:245-250.
4. 1 antihistamines. Ann Allergy 1991;67:625-633.
5. 1-receptor antagonists; comparative tolerability and safety. Drug Saf 1994;10:350-380.
6. 1 receptors evaluated with [3H] mepyramine may predict sedative properties of psychotropic drugs. Eur J Pharmacol 1979;60:391-396.
7. 1 receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991;104:270-276.
8. 1-receptor antagonists. An EAACI position paper. Allergy 1996;51:666-675.
9. 1 receptors? J Pharm Pharmacol 1979;31:701-702.
10. AHN HS, BARNETT A. Selective displacement of [3H] mepyramine from peripheral versus central nervous system receptors by loratadine, a non-selective antihistamine. Eur J Pharmacol 1986;127:153-155.
11. 1 receptor antagonists for CNS and peripheral receptors? An in vitro study. Eur J Pharmacol 1993;232:199-205.
12. 1 receptor. Proc Natl Acad Sci U S A 1991;88:11515-11519.
13. BANKS WA, AUDUS KL, DAVIS TP. Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically-useful analogs. Peptides 1992;13:1289-1294.
14. REED DJ. Drug transport into the central nervous system. In: GLASER GH, PENTRY JK, WOODBURN DM, editors. Antiepileptic drugs: mechanisms of action. New York: Raven Press, 1980:199-205.
15. HANSCH C, BJORKROTH JP, LEO A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci 1987;76:663-687.
16. OVERTON E. Studien über die Narkose. Jena: Fisher Publishers, 1903.
17. GLAVE WR, HANSCH C. The anesthetic action of volatile aliphatic ethers. J Pharm Sci 1972;61:598.
18. BIAGI GL, BARBARO AM, GUERRA MC, et al. The relationship between lipophilicity and central action of benzodiazepines. J Med Chem 1980;23:193.
19. TIMMERMANS PBMVM, BRANDS A, VAN ZWIETEN PA. Lipophilicity and brain disposition of clonidine and structurally related imidazolines. Archiv Phar (Weinheim) 1977;300:217-226.
20. 1 antihistaminic agents in relation to their central sedative effects. Eur J Pharmacol Sci 1994;2:373-384.
21. 2-receptor histamine antagonists. J Med Chem 1998;31:656-671.
22. SCHINKEL AH, SMITH JJM, VAN TELLINGEN O, et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
23. HAIT WN, GESMONDE JF, MURREN JR, YANG JM, CHEN HX, REIN M. Terfenadine (Seldane®): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol 1993;45:401-406.
24. BERLIN J, KING AC, TUTSCH K, et al. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Invest New Drugs 1994;12:137-144.
25. BARTUS RT, ELLIOTT PJ, DEAL RL, et al. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol 1996;142:14-28.
26. RAPOPORT SI. Modulation of blood brain barrier permeability. J Drug Target 1996;3:417-425.
27. LEURS R, SMIT MJ, TIMMERMAN H. Molecular pharmacological aspects of histamine receptors. Pharmacol Ther 1995;66:413-463.
28. 1-receptor antagonists in allergic disease. New York: Marcel Dekker, 1996:383-412.
29. 1-agonisls. J Comput Aided Mol Des 1995;9:319-339.
30. 1-receptor antagonist. J Med Chem 1998;41:853-863.